4DMedical (4DX) Life Sciences Virtual Investor Forum summary

Company overview and recent developments

• Specializes in cardiothoracic imaging with operations across three continents and recent expansion into Europe.

• Holds nine FDA approvals and is included in the S&P/ASX 200 index.

• Recent acquisition in Europe strengthens presence and supports global growth.

Product innovation and market impact

• CT:VQ, the third-generation flagship product, enables functional lung imaging using existing CT infrastructure, eliminating the need for new hardware.

• CT:VQ provides high-resolution, 3D ventilation and perfusion images without radioactive agents, replacing traditional nuclear VQ scans.

• Adoption of CT:VQ improves patient experience, reduces delays, and enhances workflow efficiency for surgeries and disease management.

Economic and clinical advantages

• CT:VQ offers significant economic benefits, with up to AUD 1,500 upside per commercial customer and AUD 885 per Medicare patient.

• Clinical studies show improved surgical outcomes, with LVRS success rates rising from 46% to 76% using CT:VQ.

• Hospitals and radiology providers benefit from higher reimbursements and improved operating room efficiency.